Christine Schmid-Tannwald to Radiopharmaceuticals
This is a "connection" page, showing publications Christine Schmid-Tannwald has written about Radiopharmaceuticals.
Connection Strength
0.370
-
Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients. Radiol Oncol. 2024 09 01; 58(3):348-356.
Score: 0.195
-
Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med. 2014 Feb; 55(2):198-203.
Score: 0.095
-
Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy. Theranostics. 2025; 15(13):6444-6453.
Score: 0.052
-
Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense? J Nucl Med. 2016 08; 57(8):1177-82.
Score: 0.028